Neuroimmunoendocrinal markers of prediction of preeclampsia

Authors

  • D. Ye. Barkovskyi Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1237.2018.3.151718

Keywords:

pregnancy, pre-eclampsia, homeostasis, neuroendocrine system, insulin resistance, immune system, cytokines

Abstract

Objective: to establish the features of neuroendocrine regulation of homeostasis and the immune system of a woman in the 1 st trimester of pregnancy complicated by preeclampsia, and to establish prognostic criteria for the occurrence of this obstetric complication.
Materials and methods. A dynamic observation of the course of pregnancy, childbirth and the postpartum period was carried out in women pregnant for the fist time from the early stages of gestation (7–8 weeks); of these, 46 women were selected for whom the pregnancy was complicated by preeclampsia and who formed the following clinical groups: the 1 st group – 32 pregnant women with mild preeclampsia; the 2nd group – 14 pregnant women with severe preeclampsia. The control group – 48 somatically healthy pregnant women with the physiological course of pregnancy. In the serum of pregnant clinical observation groups in the 1 st (10–14 weeks), in the 2nd (23–26 weeks) and in the 3rd trimesters (32–35 weeks), the concentration of adrenocorticotropic hormone, β-endorphin was determined by ELISA , cortisol, insulin, placental lactogen, human chorionic gonadotropin, α-fetoprotein; the concentration of lymphocytes and markers of their activation (CD3, CD4, CD8, CD14, CD16,
CD19, CD25, CD71, CD95, HLA DR) was determined by the immunoflorescence method using monoclonal antibodies.
Results. For the women with the preeclampsia of the 1 st degree the neuroendocrinal regulation of homeostasis is broken in the 1 st trimester of pregnancy with creation of primary placental insuffiency, oppression of the stress-realizing function of the hypothalamo-pituitary system, development of insulin resistance, that as a whole testifis about dysadaptation of an
organism of the women in the 1 st trimester of pregnancy. In the 1 st trimester the state of the fetoplacental complex for the pregnant women with preeclampsia, regardless of the degree of severity, is characterized by the dysbalance of hormones production, which testifis to development of primary placental insuffiency.
Conclusions. For the women with preeclampsia of mild degree dysbalance of the immune system develops already in the 1 st trimester of pregnancy as relative augmentation of total of T-lymphocytes with simultaneous decrease of their functional activity, particularly Т-helpers of the 2nd type, which is accompanied by the decrease of anti-inflmmatory cytokines production.
For the women with preeclampsia of serious degree the quantitative parameters of non-specifi and cellular immunity (CD3, CD4, CD8, CD16, HLA-DR) are reduced already in 1 st trimester of pregnancy with simultaneous rising of the value of immunoregulatory index (CD4/CD8) and functional activity of Т-helpers of the 1 st type on the background of the activity oppression of the 2nd type Т-helpers.

References

Ahmad, A., & Samuelsen, S. (2012). Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies. BJOG: An International Journal Of Obstetrics & Gynaecology, 119(12), 1521–1528. doi: 10.1111/j.1471-0528.2012.03460.x.

Lindheimer, M., Taler, S., & Cunningham, F. (2010). Hypertension in pregnancy. Journal Of The American Society Of Hypertension, 4(2), 68–78. doi: 10.1016/j.jash.2010.03.002.

Say, L., Chou, D., Gemmill, A., Tunçalp, Ö., Moller, A., Daniels, J. et al. (2014). Global causes of maternal death: a WHO systematic analysis. The Lancet Global Health, 2(6), e323–e333. doi: 10.1016/s2214-109x(14)70227-x.

Folic, M., Folic, N., Varjacic, M., Jakovljevic, M., & Jankovic, S. (2008). Antihypertensive drug therapy for hypertensive disorders in pregnancy. Acta Medica Medianae, 47, 65–72.

Kuklina, E., Ayala, C., & Callaghan, W. (2009). Hypertensive Disorders and Severe Obstetric Morbidity in the United States. Obstetrics & Gynecology, 113(6), 1299–1306. doi: 10.1097/aog.0b013e3181a45b25.

Ayansina, D., Black, C., Hall, S., Marks, A., Millar, C., Prescott, G. et al. (2016). Long term effects of gestational hypertension and pre-eclampsia on kidney function: Record linkage study. Pregnancy Hypertension: An International Journal Of Women's Cardiovascular Health, 6(4), 344–349. doi: 10.1016/j.preghy.2016.08.231.

Gathiram, P., & Moodley, J. (2016). Pre-eclampsia: its pathogenesis and pathophysiolgy. Cardiovascular Journal Of Africa, 27(2), 71–78. doi: 10.5830/cvja-2016-009.

Malik, R., & Kumar, V. (2017). Hypertension in Pregnancy. Advances In Experimental Medicine And Biology, 956, 375–393. doi: 10.1007/5584_2016_150.

Goulopoulou, S. (2017). Maternal Vascular Physiology in Preeclampsia. Hypertension, 70(6), 1066–1073. doi: 10.1161/hypertensionaha.117.08821.

Boeldt, D., & Bird, I. (2017). Vascular adaptation in pregnancy and endothelial dysfunction in preeclampsia. Journal Of Endocrinology, 232(1), R27–R44. doi: 10.1530/joe-16-0340.

Chiarello, D., Marín, R., Proverbio, F., Coronado, P., Toledo, F., Salsoso, R., et al. (2018). Mechanisms of the effect of magnesium salts in preeclampsia. Placenta, 69, 134–139. doi: 10.1016/j.placenta.2018.04.011.

Chaiworapongsa, T., Chaemsaithong, P., Yeo, L., & Romero, R. (2014). Pre-eclampsia part 1: current understanding of its pathophysiology. Nature Reviews Nephrology, 10(8), 466–480. doi: 10.1038/nrneph.2014.102.

Moussa, H., Arian, S., & Sibai, B. (2014). Management of Hypertensive Disorders in Pregnancy. Women's Health, 10(4), 385–404. doi: 10.2217/whe.14.32.

Dhariwal, N., & Lynde, G. (2017). Update in the Management of Patients with Preeclampsia. Anesthesiology Clinics, 35(1), 95–106. doi: 10.1016/j.anclin.2016.09.009.

Harmon, A., Cornelius, D., Amaral, L., Faulkner, J., Cunningham, M., Wallace, K., & LaMarca, B. (2016). The role of inflammation in the pathology of preeclampsia. Clinical Science, 130(6), 409–419. doi: 10.1042/cs20150702.

Meher, S., Duley, L., Hunter, K., & Askie, L. (2017). Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: an individual participant data meta-analysis. American Journal Of Obstetrics And Gynecology, 216(2), 121–128.e2. doi: 10.1016/j.ajog.2016.10.016.

Ader, R. (ed) (2006). Psychoneuroimmunology. Oxford: Elsevier Academic. I, 39–251.

Christian, L. (2012). Physiological reactivity to psychological stress in human pregnancy: Current knowledge and future directions. Progress In Neurobiology, 99(2), 106–116. doi: 10.1016/j.pneurobio.2012.07.003.

Christian, L. (2012). Psychoneuroimmunology in pregnancy: Immune pathways linking stress with maternal health, adverse birth outcomes, and fetal development. Neuroscience & Biobehavioral Reviews, 36(1), 350–361. doi: 10.1016/j.neubiorev.2011.07.005.

Christian, L., Franco, A., Iams, J., Sheridan, J., & Glaser, R. (2010). Depressive symptoms predict exaggerated inflammatory responses to an in vivo immune challenge among pregnant women. Brain, Behavior, And Immunity, 24(1), 49–53. doi: 10.1016/j.bbi.2009.05.055.

Moffett, A., & Colucci, F. (2014). Uterine NK cells: active regulators at the maternal-fetal interface. Journal Of Clinical Investigation, 124(5), 1872–1879. doi: 10.1172/jci68107.

Matthiesen, L., Berg, G., Ernerudh, J., Ekerfelt, C., Jonsson, Y., & Sharma, S. (2005). Immunology of Preeclampsia. Chemical Immunology And Allergy, 89, 49–61. doi: 10.1159/000087912.

Mikhailova, V., Ovchinnikova, O., Zainulina, M., Sokolov, D., & Sel’kov, S. (2014). Detection of Microparticles of Leukocytic Origin in the Peripheral Blood in Normal Pregnancy and Preeclampsia. Bulletin Of Experimental Biology And Medicine, 157(6), 751–756. doi: 10.1007/s10517-014-2659-x.

Nguyen, T., Kahn, D., & Loewendorf, A. (2017). Maternal–Fetal rejection reactions are unconstrained in preeclamptic women. PLOS ONE, 12(11), e0188250. doi: 10.1371/journal.pone.0188250.

Szarka, A., Rigo, J., Lazar, L., Beko, G., & Molvarec, A. (2010). Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunology, 11, 59. doi: 10.1186/1471-2172-11-59.

van Rijn, B., Veerbeek, J., Scholtens, L., Uiterweer, E., Koster, M., Peeters, L., et al. (2014). C-reactive protein and fibrinogen levels as determinants of recurrent preeclampsia. Journal Of Hypertension, 32(2), 408–414. doi: 10.1097/hjh.0000000000000027.

Roiz-Hernández, J., Cabello-Martínez, J., & Fernández-Mejía, M. (2005). Human chorionic gonadotropin levels between 16 and 21 weeks of pregnancy and prediction of pre-eclampsia. International Journal Of Gynecology & Obstetrics, 92(2), 101–105. doi: 10.1016/j.ijgo.2005.10.002.

Mallick, M., Ray, S., Medhi, R., & Bisai, S. (2015). Elevated serum βhCG and dyslipidemia in second trimester as predictors of subsequent Pregnancy Induced Hypertension. Bangladesh Medical Research Council Bulletin, 40(3), 97. doi: 10.3329/bmrcb.v40i3.25230.

Begum, Z., Ara, I., Tanira, S., & Keya, K. (2015). The association between serum betahuman Chorionic gonadotropin and Preeclampsia. Journal Of Dhaka Medical College, 23(1), 89–93. doi: 10.3329/jdmc.v23i1.22701.

Bhattacharjee, A., Deka, G., Begum, F., & Bayan, M. (2016). Elevated maternal serum alpha fetoprotein (MSAFP) level in second trimester as a screening test for predicting adverse pregnancy outcome. The New Indian Journal Of OBGYN, 3(1), 20–3. doi: 10.21276/obgyn.2016.3.1.4.

Başbuğ, D., Başbuğ, A., & Gülerman, C. (2017). Is unexplained elevated maternal serum alpha-fetoprotein still important predictor for adverse pregnancy outcome? Ginekologia Polska, 88(6), 325–330. doi: 10.5603/gp.a2017.0061.

How to Cite

1.
Barkovskyi DY. Neuroimmunoendocrinal markers of prediction of preeclampsia. Pathologia [Internet]. 2018Dec.19 [cited 2024Apr.19];(3). Available from: http://pat.zsmu.edu.ua/article/view/151718

Issue

Section

Original research